

> **ì£¼ì œ:** IV(ì •ë§¥ì£¼ì‚¬) â†’ SC(í”¼í•˜ì£¼ì‚¬) ì œí˜• ì „í™˜ì„ ìœ„í•œ ëª¨ë¸ë§ í”„ë ˆì„ì›Œí¬  
> **ëª©ì :** í•­ì²´ì¹˜ë£Œì œì˜ ì•½ë™í•™(PK) ê¸°ë°˜ SC ì œí˜• ìµœì í™” ë°ì´í„° êµ¬ì¶• ë° ì˜ˆì¸¡ëª¨í˜• ì„¤ê³„  
> **êµ¬ì„±:** â‘  SC ê°œë°œ ì„±ê³¼ ì •ë¦¬ â‘¡ ìµœì†Œ ë³€ìˆ˜ ì„¸íŠ¸(MVD) â‘¢ í…ìŠ¤íŠ¸ ì„ë² ë”© ë³€ìˆ˜ â‘£ ì‹¤ìŠµ ë° ê³¼ì œ

## 1ï¸âƒ£ ë‹¨ì¼í•­ì²´ í”¼í•˜ì£¼ì‚¬(SC) ì œí˜• ê°œë°œ ì„±ê³¼ ìš”ì•½ (2025 ê¸°ì¤€)

|SCëª…|IVëª…|ì„±ë¶„ëª…|ì„±ê³¼|
|---|---|---|---|
|Herceptin Hylecta / Herceptin SC|Herceptin|Trastuzumab|âœ… ì„±ê³µ|
|Darzalex Faspro|Darzalex|Daratumumab|âœ… ì„±ê³µ|
|Rituxan Hycela / MabThera SC|Rituxan / MabThera|Rituximab|âœ… ì„±ê³µ|
|Kesimpta|Arzerra|Ofatumumab|âœ… ì„±ê³µ|
|Xolair SC|Xolair (ì´ˆê¸° IV ë²„ì „)|Omalizumab|âœ… ì„±ê³µ|
|Nucala SC|Nucala (IV)|Mepolizumab|âœ… ì„±ê³µ|
|Fasenra SC|Fasenra (IV)|Benralizumab|âœ… ì„±ê³µ|
|Lecanemab SC|Leqembi (IV)|Lecanemab|âœ… ì„±ê³µ|
|Eculizumab SC / Ravulizumab SC|Soliris / Ultomiris|Eculizumab|âœ… ì„±ê³µ|
|Entyvio SC|Entyvio (IV)|Vedolizumab|âœ… ì„±ê³µ|
|Keytruda Qlex (SC)|Keytruda|Pembrolizumab|âš ï¸ ì§€ì²´ (í—ˆê°€ ì§„í–‰ ì¤‘)|
|Opdivo Qvantig (SC)|Opdivo|Nivolumab|âš ï¸ ì§€ì²´ (í—ˆê°€ ëŒ€ê¸°)|
|Tecentriq Hybreza (SC)|Tecentriq|Atezolizumab|âš ï¸ ì§€ì²´ (ì„ìƒ ì¢…ë£Œ â†’ í—ˆê°€ ì§„í–‰ ì¤‘)|
|Eptinezumab SC|Vyepti|Eptinezumab|âš ï¸ ì§€ì²´ (1ìƒ ì§„í–‰ ì¤‘)|
|Teprotumumab SC|Tepezza (IV)|Teprotumumab|âš ï¸ ì§€ì²´ (ì ë„ ë¬¸ì œë¡œ ì§€ì—°)|
|Durvalumab SC|Imfinzi|Durvalumab|âš ï¸ ì§€ì²´ (ì„ìƒ ì§„í–‰ ëŠë¦¼)|
|Remicade SC / CT-P13 SC|Remicade (IV)|Infliximab|âš ï¸ ì§€ì²´ (êµ­ê°€ë³„ í—ˆê°€ ì§€ì—°)|
|Actemra SC (Pen)|Actemra (IV)|Tocilizumab|âŒ ì‹¤íŒ¨ (ëŒ€ëŸ‰ ì¹˜ë£Œìš© ì „í™˜ ë¶ˆê°€)|
|Bevacizumab SC|Avastin|Bevacizumab|âŒ ì‹¤íŒ¨ (ê³ ì ë„Â·ì£¼ì…ë¶ˆê°€)|
|Cetuximab SC|Erbitux|Cetuximab|âŒ ì‹¤íŒ¨ (í¡ìˆ˜ìœ¨ ë¶ˆê· ì¼Â·ë©´ì—­ë°˜ì‘)|
|Alemtuzumab SC|Lemtrada|Alemtuzumab|âŒ ì‹¤íŒ¨ (í”¼í•˜ í¡ìˆ˜ ë¶ˆëŸ‰Â·ë¶€ì‘ìš©)|
|Ipilimumab SC|Yervoy|Ipilimumab|âŒ ì‹¤íŒ¨ (PK ë¶ˆëŸ‰ ë° ë…ì„± ì¦ê°€)|

ğŸ’¡ _ì„±ê³µ 10ì¢… / ì§€ì²´ 7ì¢… / ì‹¤íŒ¨ 5ì¢…_  
â†’ SC ì„±ê³µì˜ í•µì‹¬ì€ **ê³ ë†ì¶• ì œí˜• ì•ˆì •í™” + hyaluronidase ë³‘ìš© + F(ìƒì²´ì´ìš©ë¥ ) í™•ë³´**

---

## 2ï¸âƒ£ ìµœì†Œ ë³€ìˆ˜ ì„¸íŠ¸ (MVD â€“ 20 Variables)

|êµ¬ë¶„|ë³€ìˆ˜ëª…|ë‹¨ìœ„|ë³€ìˆ˜ìœ í˜•|ì„¤ëª…|
|---|---|---|---|---|
|**Formulation**|conc_mg_per_ml|mg/mL|ìˆ˜ì¹˜í˜•|í•­ì²´ ë†ë„|
||viscosity_cp|cP|ìˆ˜ì¹˜í˜•|ì ë„ (íˆ¬ì—¬ ê°€ëŠ¥ì„± ì œí•œ)|
||inj_volume_ml|mL|ìˆ˜ì¹˜í˜•|ì£¼ì… ë¶€í”¼|
||pH|â€“|ìˆ˜ì¹˜í˜•|ì•ˆì •ì„±Â·í¡ìˆ˜ì„± ê´€ë ¨|
||additive_type|â€“|ë²”ì£¼í˜•|ì§ˆì†Œ, ë§Œë‹ˆí†¨ ë“± ì²¨ê°€ì œ|
||enzyme_ratio|%|ìˆ˜ì¹˜í˜•|í•­ì²´ ëŒ€ë¹„ íš¨ì†Œë¹„ìœ¨|
|**PK â€“ IV**|CL_IV|mL/h/kg|ìˆ˜ì¹˜í˜•|IV ì²­ì†Œìœ¨|
||Vd_IV|L/kg|ìˆ˜ì¹˜í˜•|ë¶„í¬ìš©ì |
||t_half_IV|h|ìˆ˜ì¹˜í˜•|ë°˜ê°ê¸°|
||AUC_IV|Î¼gÂ·h/mL|ìˆ˜ì¹˜í˜•|ê¸°ì¤€ ë…¸ì¶œëŸ‰|
||Cmax_IV|Î¼g/mL|ìˆ˜ì¹˜í˜•|ìµœëŒ€ë†ë„|
|**PK â€“ SC (target)**|Ka_SC|hâ»Â¹|ìˆ˜ì¹˜í˜•|í¡ìˆ˜ì†ë„ìƒìˆ˜|
||F_SC|%|ìˆ˜ì¹˜í˜•|ìƒì²´ì´ìš©ë¥  (AUC_SC / AUC_IV Ã— 100)|
||AUC_SC|Î¼gÂ·h/mL|ìˆ˜ì¹˜í˜•|SC ë…¸ì¶œëŸ‰|
|**Antibody Descriptor**|MW|kDa|ìˆ˜ì¹˜í˜•|ë¶„ìëŸ‰|
||pI|â€“|ìˆ˜ì¹˜í˜•|ë“±ì „ì |
||glyco_content|%|ìˆ˜ì¹˜í˜•|ë‹¹í™”ìœ¨|
|**Administration**|inj_rate_ml_min|mL/min|ìˆ˜ì¹˜í˜•|ì£¼ì…ì†ë„|
||injection_site|â€“|ë²”ì£¼í˜•|ë³µë¶€, ëŒ€í‡´ë¶€ ë“±|
||BMI|kg/mÂ²|ìˆ˜ì¹˜í˜•|í™˜ì ìƒë¦¬ì  í¡ìˆ˜ ì°¨ ë°˜ì˜|

ğŸ’¡ ëŒ€ë¶€ë¶„ ê³µê°œ ë¬¸í—Œ, FDA/EMA ë¼ë²¨, ì„ìƒì‹œí—˜ ê²°ê³¼ë¡œ í™•ë³´ ê°€ëŠ¥  
â†’ **ì˜ˆì¸¡ ëª©í‘œ(Target)** : `Ka_SC`, `F_SC`  
â†’ **í•™ìŠµ ì…ë ¥(Features)** : Formulation + IV PK + Antibody íŠ¹ì„± + Administration

---

## 3ï¸âƒ£ í…ìŠ¤íŠ¸ ê¸°ë°˜ ì„ë² ë”© ë³€ìˆ˜ (ì—°êµ¬ì˜ ì°¨ë³„ì )

|ì¹´í…Œê³ ë¦¬|ë³€ìˆ˜ëª…|í˜•íƒœ|ì„¤ëª…|í™œìš© ì˜ˆì‹œ|
|---|---|---|---|---|
|ë¼ë²¨ ë¬¸êµ¬ (Label-based)|`label_summary_text`|Text|FDA/EMA í—ˆê°€ì„œì˜ PK SummaryÂ·íˆ¬ì—¬ ì¡°ê±´ ë¬¸ì¥|â€œA 600 mg SC dose provides equivalent exposure to 8 mg/kg IV.â€|
|ë…¼ë¬¸Â·íŠ¹í—ˆ ê¸°ìˆ ìš”ì•½|`formulation_description`|Text|ì œí˜• ì¡°ì„±Â·ì²¨ê°€ì œÂ·ê¸°ìˆ  ìš”ì•½|â€œCo-formulated with recombinant hyaluronidase to reduce viscosity.â€|
|í¡ìˆ˜ ë©”ì»¤ë‹ˆì¦˜ ìš”ì•½|`absorption_mechanism`|Text|diffusion / lymphatic pathway ê´€ë ¨ ì„œìˆ |â€œAbsorption mainly via lymphatic drainage.â€|
|ì•ˆì „ì„± ë¬¸ë§¥|`safety_text`|Text|injection-site reaction, ADA ë¬¸êµ¬|â€œLocal reactions were mild and transient.â€|
|ì œì¡°ì‚¬ ê°œë°œë…¸íŠ¸ / íŠ¹í—ˆìš”ì•½|`tech_background`|Text|ì œì¡°ê³µì •Â·ë†ì¶• ê¸°ìˆ  ê´€ë ¨ ë¬¸ì¥|â€œHigh-concentration formulation stabilized by histidine buffer.â€|

ğŸ’¡ _ì„ë² ë”© ëª¨ë¸ ì˜ˆì‹œ:_ `text-embedding-3-large` (OpenAI) or `BioBERT`  
â†’ í…ìŠ¤íŠ¸ ë²¡í„°ë¥¼ ìˆ˜ì¹˜ë³€ìˆ˜ì™€ ê²°í•©í•˜ì—¬ â€œë¬¸í—Œ ê¸°ë°˜ ì œí˜•ì§€ì‹ + PK ë°ì´í„°â€ ìœµí•© ì˜ˆì¸¡ ê°€ëŠ¥

## 4ï¸âƒ£ ë°œí‘œ ë‚´ìš© (Assignments)

### ğŸ§  **ë°ì´í„° êµ¬ì¶•**

- í•­ì²´ 3ì¢…(ì„±ê³µ, ì§€ì²´, ì‹¤íŒ¨)ì„ ì„ íƒí•˜ì—¬, IVâ€“SC ì „í™˜ ë°ì´í„°ë¥¼ ìˆ˜ì§‘í•˜ì‹œì˜¤.
        
- ê° í•­ì²´ë³„ë¡œ ìµœì†Œ ë³€ìˆ˜(MVD-20)ë¥¼ ë¬¸í—Œì—ì„œ ì¶”ì¶œ(í”„ë¡¬í”„íŠ¸ë¡œ í•´ê²°í•  ìˆ˜ ìˆëŠ”ì§€ ê°€ëŠ¥ì„± íƒ€ì§„)
    
- ì¶œì²˜(FDA label, PubMed, ClinicalTrials.gov ë§í¬ í¬í•¨) ê¸°ë¡
    

### ğŸ’» **í…ìŠ¤íŠ¸ ì„ë² ë”© ìƒì„±**

- í—ˆê°€ ë¬¸ì„œ ë˜ëŠ” ë…¼ë¬¸ ì´ˆë¡ì—ì„œ ì„ë² ë”© ë³€ìˆ˜ê°’ì„ ì¶”ì¶œí•˜ê³  ì„ë² ë”© ë²¡í„°ë¥¼ ìƒì„±í•˜ì‹œì˜¤.
         
- `text-embedding-3-large` ì‚¬ìš©